Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 14.95B 855M 748M 687M 641M 1.22B 81.45B 1.23B 8.25B 3.21B 40.04B 3.21B 3.14B 138B P/E 2026 *
6.98x
P/E 2027 * 6.91x
Enterprise Value 18.81B 1.08B 941M 865M 806M 1.53B 102B 1.55B 10.38B 4.04B 50.38B 4.04B 3.95B 174B EV / Sales 2026 *
1.03x
EV / Sales 2027 * 0.96x
Free-Float
68.95%
Yield 2026 *
5.23%
Yield 2027 * 7.16%
24/04 Genomma Lab Internacional, S.A.B. de C.V., Q1 2026 Earnings Call, Apr 23, 2026
24/04 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
27/02 Genomma Lab Internacional, S.A.B. de C.V., Q4 2025 Earnings Call, Feb 26, 2026
26/02 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
10/12 Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025 CI
24/10/25 Genomma Lab Internacional, S.A.B. de C.V., Q3 2025 Earnings Call, Oct 23, 2025
22/10/25 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25/07/25 Genomma Lab Internacional, S.A.B. de C.V., Q2 2025 Earnings Call, Jul 24, 2025
23/07/25 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
24/06/25 Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025 CI
05/06/25 Genomma Lab Successfully Issued the Lab 25 and Lab 25-2 Unsecured Bonds for A Total Amount of $1.2 Billion Pesos, Which Will Be Used to Prepay Liabilities, Including the Full Early Amortization of the Lab 23 Bond CI
02/05/25 Genomma Lab Internacional, S.A.B. de C.V., Q1 2025 Earnings Call, May 02, 2025
01/05/25 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day+0.66%
1 week+2.47%
Current month+2.00%
3 months-18.37%
6 months-14.50%
Current year-14.31%
1 week 14.65
Extreme 14.65
15.7
1 month 14.24
Extreme 14.24
15.7
Current year 14.24
Extreme 14.24
19.48
1 year 14.24
Extreme 14.24
23.6
3 years 12.39
Extreme 12.39
29.18
5 years 12.39
Extreme 12.39
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 12/04/2023
Director of Finance/CFO - 01/12/2015
Investor Relations Contact - 01/10/2019
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - 01/01/2017
Chairman - 30/10/1996
Change 5-day change 1-year change 3-year change Capi.($)
+0.66%+2.47%-25.73%+10.77% 855M
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+31.35%+24.29% 338B
-0.56%+0.96%+39.86%+36.64% 299B
-0.08%+1.30%+30.37%+44.02% 291B
-1.54%+2.81%-27.56%-39.45% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.95%+4.40%+25.32%+53.11% 369.33B
Weighted average by Cap. +2.24%+5.53%+41.76%+82.99%

Financials

2026 *2027 *
Net sales 18.32B 1.05B 916M 842M 785M 1.49B 99.82B 1.51B 10.11B 3.93B 49.07B 3.94B 3.85B 169B 19.24B 1.1B 962M 884M 824M 1.56B 105B 1.59B 10.62B 4.13B 51.52B 4.13B 4.04B 178B
Net income 2.14B 122M 107M 98.21M 91.55M 174M 11.64B 176M 1.18B 458M 5.72B 459M 449M 19.72B 2.25B 129M 113M 103M 96.44M 183M 12.26B 186M 1.24B 483M 6.03B 483M 473M 20.77B
Net Debt 3.86B 221M 193M 178M 165M 314M 21.04B 319M 2.13B 828M 10.34B 829M 812M 35.64B 3.46B 198M 173M 159M 148M 282M 18.87B 286M 1.91B 743M 9.28B 744M 728M 31.96B
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,643
Date Price Change Volume
03/07/26 MXN 15.33 +0.66% 493,025
02/07/26 MXN 15.23 -2.37% 3,487,891
01/07/26 MXN 15.60 +3.79% 3,977,498
30/06/26 MXN 15.03 +0.80% 6,164,745
29/06/26 MXN 14.91 -0.33% 2,412,960
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.33MXN
Average target price
24.40MXN
Spread / Average Target
+59.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LAB B Stock